52 Week Range
As of on the Virt-X ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Lonza And Be The Match Biotherapies Partner To Expand Vein-To-Vein Cell And Gene Therapy Supply Chain Network
Lonza Expands Highly Potent Drug Product Development and Manufacturing Capabilities
Lonza Announces Collaboration With Fujifilm Cellular Dynamics
Lonza Group AG (Lonza) is a Switzerland-based holding company and a supplier to the pharmaceutical, healthcare and life science industries. The Company's offerings include custom development and manufacturing of drugs and drug delivery systems, as well as development of anti-microbial solutions for commercial applications. The Company divides its activities into two segments: Pharma&Biotech and Specialty Ingredients. The Pharma&Biotech comprises the Company's Biologics, Small-Molecule, and Consumables and Research Tools businesses. The segment includes mammalian, microbial, chemical, bioconjugates, cell and gene therapy technology platforms. The Specialty Ingredients segment focuses on anti-microbial applications within Consumer Health division, which covers hygiene, nutrition and personal care products, as well as preservatives, capsules and food supplements, among others, and Consumer & Resources Protection division, which includes coatings and composites, and agro ingredients.
Biotechnology & Drugs
Albert M. Baehny
Chairman of the Board, Member of the Executive Board
Chief Executive Officer
Chief Financial Officer, Member of the Executive Committee
Chief Human Resource Officer, Member of the Executive Committee
Chief Operating Officer of Lonza Pharma Biotech and Nutrition, Member of the Executive Committee
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
Lonza Group has agreed with AstraZeneca to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, the Swiss contract manufacturer said on Friday.
Swiss contract manufacturer Lonza Group is adding a mid-scale microbial facility to supply France's Laboratoires Servier with active pharmaceutical ingredient for acute lymphoblastic leukaemia therapies, Lonza said on Tuesday.
Lonza Group said on Monday that China's Junshi Biosciences has licensed the Swiss contract drug manufacturer's technology to help produce a neutralizing antibody against COVID-19.
Lonza Group AG is in the “last step” of discussions with U.S. regulators for approval to claim that its formulation is effective in killing the novel Coronavirus on surfaces, an executive at the pharmaceutical and chemical giant told Reuters.
* LONZA ESTABLISHES A NEW CENTER OF EXCELLENCE TO LEVERAGE ITS CORE PARTICLE ENGINEERING EXPERTISE UTILIZING BOTH PARTICLE SIZE REDUCTION AND SPRAY DRYING TECHNOLOGIES
Lonza Group Chief Operating Officer Sven Abend, also head of its Lonza Specialty Ingredients (LSI) business, is resigning to become chief executive of an unnamed German company, the Swiss contract manufacturer said on Tuesday.
* HAS COLLABORATED WITH CELLINK TO OFFER A COMPREHENSIVE 3-DIMENSIONAL (3D) BIOPRINTING SOLUTION
Lonza Group on Friday named a veteran Roche manager to become its new chief executive, as the Swiss contract drug manufacturer seeks to end a year of turmoil at the top and accelerates work to produce a possible COVID-19 vaccine.
Swiss contract drug manufacturer Lonza Group on Friday named Roche executive Pierre-Alain Ruffieux as its new chief executive effective from Nov. 1.
* LONZA GROUP LTD (REQUEST FOR TRADING HALT) Source text for Eikon: Further company coverage:
Moderna Inc and Swiss contract drugmaker Lonza Group AG said on Friday they would accelerate the manufacturing of the U.S. drug developer's potential coronavirus vaccine.
Lonza on Friday said it would go ahead with its annual general meeting on April 28 without shareholders present, leaving its dividend proposal of 2.75 Swiss francs ($2.81) per share unchanged. ($1 = 0.9800 Swiss francs) (Reporting by Brenna Hughes Neghaiwi Editing by Michelle...
* LONZA CHAIRMAN SAYS LONG-TERM STRATEGIC FOCUS IS ON BIOTECH, DRUG AND NUTRITION BUSINESS, OPTIONS FOR SPECIALTY CHEMICALS INCLUDE SALE, SPINOFF, IPO OR KEEP IN PORTFOLIO
* LONZA ANNOUNCES PRICE INCREASES FOR SELECTED PRODUCTS IN ITS QUATS, AMINES AND AMINE OXIDES PORTFOLIOS GLOBALLY
* SAYS IBEX SOLUTIONS TO SUPPORT GENMAB’S GROWING CLINICAL PORTFOLIO
Lonza Group's <LONN.S> first-half profit plunged as it took losses linked to the sale of its water business and as difficulties at its specialty ingredients business continued, though the Swiss drug ingredients maker confirmed full-year targets.
* LONZA EXPANDS BIOCONJUGATION FACILITY AND ANNOUNCES APPROVAL OF THIRD COMMERCIAL ADC
Swiss drug ingredients maker Lonza Group said on Wednesday it is on pace to hit its 2019 goal of mid-to-high single-digit sales growth as double-digit gains in its drug and biotech unit in the first half offset weaker business elsewhere.
Lonza Group is buying a drug bottling plant from Novartis in northern Switzerland as the Swiss drug ingredients maker fills a gap in its offering for drugmakers seeking to outsource production.
Lonza Group is buying a sterile fill-and-finish facility from Novartis as the Swiss drug ingredients maker boosts its offering for pharmaceuticals companies.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.